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ABSTRACT
O b j e c t ive : To eva l u ate hy p e rs o m n o -
lence in patients affected by fibromyal -
gia syndrome.
Methods: Thirty consecutive patients
a ffected by fi b ro mya l gia syndro m e
(FMS) (28 F) completed a sleep ques -
tionnaire and underwent the following
evaluations: lung function tests; poly -
somnography; the Epworth sleepiness
scale (ESS), wh i ch measures sleep com -
plaints and daytime hypersomnolence;
and the visual analogical scale (VAS)
to detect subjective pain, fatigue, anxi -
ety and depression.
Results: The FMS patients were divid -
ed into two groups based on their ESS
score. Patients complaining of daytime
hypersomnolence had a higher number
of tender points (15 ±2 vs. 12 ±1, p<
0.01), a higher subjective pain score
(72±15 vs. 52±13, p<0.05),and more
fatigue (p<0.05). The diffusing capaci -
ty of the lung (Tlco) was more impaired
and the occurrence of periodic breath -
ing was higher. FMS patients com -
plaining of daytime somnolence had
s i g n i fi c a n t ly less efficient sleep than
the FMS patients with no daytime som -
nolence (p <0.05), i.e. a lower propor -
tion of stage 3 sleep (5± 2% vs. 12 ±
3%; p < 0.001), stage 4 sleep (1± 0.5%
v s .4±1 % ;p<0 . 0 0 1 ) , and twice as many
arousals per hour of sleep (p < 0.01).
The re s p i rat o ry pat t e rn of FMS pa -
tients with hypersomnolence showed a
higher occurrence of periodic breath -
ing (p<0.05). The short length of apno -
as and hypopnoeas did not affect the
apnea/hypopnea index (5.1 ± 3 vs. 7 ±
4; ns), but FMS patients with daytime
hypersomnolence had a greater num -
ber of desaturations per hour of sleep
(11 ±6 vs. 6± 5; p < 0.05). Pulmonary
volumes did not differ between the two
groups. The EES score was significant -
ly correlated in FMS patients, and even
m o re marke d ly in the FMS pat i e n t s
with hypersomnolence, TLco, A/I, and
disease duration. The ESS score was
correlated significantly with the num -
ber of tender points only in FMS pa -
tients with daytime hypersomnolence. 
C o n cl u s i o n : The occurrence of day -
time hypersomnolence in FMS patients
is linked to a greater severity of fibro -
myalgia symptoms and to more severe
polysomnographic alterations.
Introduction
Fi b ro mya l gia syndrome (FMS) is a
common condition causing generalized
muscle pain (1). This syndrome affects
up to 3-4% of the general population
and is one of the most common diag-
noses seen in ambu l at o ry office set-
tings. 80 to 90% of patients are women,
and the peak age is 30-50 years (2).
The criteria used for its diagnosis were
s t ated by the A m e rican College of
Rheumatology in 1990 (3). The pain is
w i d e s p re a d, lasting for at least thre e
months, bilateral, above and below the
waist, axial,and involving at least 11 of
18 specified tender points. Other char-
acteristics of the syndrome - often pre-
sent, but not essential for the diagnosis
- are chronic fatigue, migraine, irritable
bowel syndrome, headache, paresthe-
sias, Raynaud’s like symptoms, depres-
sion, anxiety and non-restorative and/
or disturbed sleep (4). 
The reported complaint of poor sleep is
so common in FMS patients that in
some case series its prevalence is near-
ly 100% (5-7). The observation that a
neurasthenic musculoskeletal pain syn-
drome can be elicited in normal volun-
teers undergoing selective deep NREM
sleep deprivation (7) seems to suggest
that a vicious circle may be in opera-
tion, with pain impaired sleep leading
to a worsening of the disease. Moldof-
sky et al. proposed an alpha intrusion
on delta sleep in 1975 (8) as a marker
of the sleep impairment typical of FMS
p at i e n t s , but this has not been con-
firmed by other studies (9, 10), while
an association between alpha intrusion
in NREM sleep and other FMS symp-
toms has been variously confirmed (11)
and rejected (5) by different trials.
The hypothesis that other disord e rs cau-
sing sleep fragmentation, such as sleep
apnea syndrome (12), might be blamed
for the non-refreshing sleep symptoms
reported by FMS patients was not con-
firmed by a controlled study (13).
However, increased daytime sleepiness
is one of the most important symptoms
in fi b ro mya l gia patients. The aim of
this study was to compare sleep com-
plaints, sleep architecture, number of
arousals,alpha-delta activity, and respi-
ratory function in patients with FMS
and hypersomnolence versus fibromy-
algia with no daytime sleepiness. 
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Materials and methods
Population. Thirty eligible consecutive
Caucasian patients (28 females) aged
51.2 ± 8.9 years with FMS, diagnosed
according to the 1990 American Col-
l ege of Rheumat o l ogy Classifi c at i o n
Criteria (3), were invited to participate
in this study. A 2-week wash-out period
for any pharm a c o l ogical tre at m e n t
re l ated to FMS was requested of all
patients. A sleep questionnaire and the
Epworth Sleepiness Scale (ESS) were
then administered to all subjects and
the FMS patients were divided in two
subsets according to the presence or ab-
sence of hypersomnolence. No differ-
ence was observed in the disease dura-
tion (7.3 ±3.1 vs. 5.9±3.8), age (52.2 ±
8.9 vs. 51.4 ± 2 yrs), sex (15/1 vs. 12/1
F/M) and body mass index (BMI) (25.8
± 3.7 vs. 25.5 ± 3.1 Kg/m2) between the
patients with and without hypersomno-
lence (HS). Informed consent was ob-
tained in all cases. The Hospital Medi-
cal Ethics Committee ap p roved the
study.
Clinical evaluation. In all subjects the
following clinical variables were evalu-
ated: examination of 18 tender points
using the protocol of Wolfe et al. (3) (a
score for number of tender points was
obtained and could range from 0 to 18);
intensity of somatic pain expressed on
a 100 mm visual analog scale (VAS);
and anxiety, depression and fatigue ex-
pressed on a 100 mm VAS [(0: absent;
100: very severe).
Study measures. A sleep questionnaire
was administered to all subjects to eval-
uate sleep complaints (12). Hypers o m-
nolence wa s evaluated according to the
ESS (14). The ESS is a questionnaire
measuring the general level of daytime
sleepiness and is the sum of eight item
scores. It can range from 0 to 24; the
“clinically” normal range of the ESS
score is 2 to 10 with a normal statistical
distribution and a model score of 6.
Po ly s o m n ograp hy.  Po ly s o m n ograp hy
(PSG) was performed in the sleep labo-
ratory, a sound attenuated room with
temperature control, using a computer-
assisted device (Alice 3 Healthdy n e,
M a ri e t t a , O H , USA). The electro e n-
c ep h a l ogra m , e l e ct ro - o c u l ogra m , a n d
submental electromyogram were recor-
ded with surface electrodes using stan-
dard techniques (15). Naso-oral ther-
mocouples and thoracic and abdominal
belts with built-on piezo electro d e s
recorded airflow and ventilatory efforts
re s p e c t ive ly. Oxyhaemoglobin sat u ra-
tion was recorded by finger pulse oxi-
m e t ry (Pulsox-7 Minolta, O s a k a ,
Japan). The transducers and lead wires
allowed normal positional changes dur-
ing sleep. Bedtime and awakening time
were at each subject’s discretion; the
polysomnography was terminated after
final awakening. In order to avoid the
first night effect, each subject spent 2
nights in the sleep laboratory; only data
recorded during the second night were
evaluated.
S l e ep and bre athing va ri ables we re
stored on an optical disk and then man-
ually scored by two physicians, blind-
ed, in 30s epochs, according to stan-
dard criteria (15). The correlation be-
tween sleep, breathing and body posi-
tion was analysed automatically by the
computer.
Apneas we re defined as 10-second
pauses in re s p i ration. Hypopnoeas we re
d e fined as a decrement in airfl ow ‡
50%, associated with either an arousal
at the end of the episode or a fall in ar-
terial oxygen saturation ‡ 4%. The res-
piratory disturbance index (RDI) was
defined as the average number of epi-
sodes of apnoea and hypopnoea per
hour of sleep and the desaturation event
f re q u e n cy (DEF) was defined as the
number of episodes of fall ‡ 4% in oxy-
h a e m oglobin sat u ration per hour of
sleep. Periodic breathing (PB) was de-
fined as a series of at least 3 successive
cycles of waxing and waning in venti-
lation, with apneas or hypopnoea.
Arousals were scored according to the
American Sleep Disorders Association
criteria (16). 
Alpha-delta intrusion was defined as
the spontaneous occurrence of alpha
waves in delta wave sleep (17). Alpha
waves usually appear during wakeful-
ness with the eyes closed or in drowsy
individuals, with a frequency of 7 to 11
cycles per second. Delta waves are the
slow waves of deep sleep, with a fre-
quency of less than 2 cycles per second,
and amplitude greater than 75 V. 
Lung function tests. All subjects under-
went body plethysmography (Bodystar
FG 90, Fenyves and Gut, Basel, Swit-
zerland), transfer factor assessment for
the lung with the single breath holding
method (TLco), i n cluding membra n e
(Dm) and capillary (Vc) components
(T.T Autolink M o rga n , A n d ove r, M A ,
USA) and bl o o d gas analysis (BG3,
I n s t ru m e n t ation Lab o rat o ry, Pa d e rn o
Dugnano, Italy).
Statistical analysis.  Data were report-
ed as mean ± standard deviation. Statis-
tical analysis of the anthro p o m e t ri c
data, polysomnographic recordings and
lung function tests was perfo rm e d
using the unpaired Student’s t test.
Pearson’s chi square was used for other
comparisons of means and proportions.
The Mann-Wh i t n ey U test and the
Spearman Rank correlation were used
where appropriate. The level of signifi-
cance was p < 0.05. All statistical ana-
lyses were performed using the statisti-
cal pack age SPSS 9.0 (SPSS Inc. ,
Chicago, IL, USA).
Results
FMS patients we re divided into two
groups according to their ESS score: 16
FMS patients with hy p e rs o m n o l e n c e
(FMS+HS) and 14 FMS patients with-
out hypersomnolence (FMS-HS).
Patients complaining of daytime hyper-
somnolence had a higher number of
tender points (p<0 . 0 1 ) , a higher subjec-
tive pain score (p < 0.05) and a signifi-
cant fatigue score (p < 0.05) (Table I).
Lung volumes (Table II) did not differ
between the two groups, but lung dif-
fusing capacity (TLco) and the diffus-
ing capacity of the alveolar membrane
(Dm) were significantly reduced in the
FMS group with hypersomnolence (p <
0.01 and 0.001, respectively). 
PSG recordings (Table III) showed that
FMS+ HS patients had lower sleep effi-
ciency (p < 0.01), and nearly twice as
many arousals per hour of sleep (A/I)
(p < 0.01). 
The percentages of stage 1 and 2 sleep
were similar in the 2 groups, although
stages 3 and 4 were markedly reduced
in the FMS+HS group (p < 0.001).
Sporadic alpha intrusion during delta
sleep was identified in 10/30 patients
(33%) with no difference between the
two FMS groups. The number/hour of
DEF during sleep were higher in FMS+
HS patients (p < 0.05). There was no
difference in the RDI, average and na-
dir SaO2 during sleep between the two
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FMS groups (Table III).
Periodic breathing was observed in 26/
30 patients (86%); the usual length of
apnoeic or hypopnoea episodes during
PB was less than 10 sec; therefore the
RDI and average SaO2 during sleep did
not differ between the two gro u p s .
N eve rt h e l e s s , PB was present for a
mean 18% of the night in FMS+HS
p atients in comparison with 11% in
FMS-HS (p < 0.05)
The ESS score was significantly corre-
lated in FMS patients, and even more
m a rke d ly in FMS+HS pat i e n t s , w i t h
Tlco,A/I and the disease duration. The
correlation between the ESS score and
PB of the total sleep time (%) was sim-
ilar in the two groups. The ESS score
was corre l ated signifi c a n t ly with the
number of tender points only in the
FMS+HS patients (Table IV). 
Discussion
Sleep architecture and hypersomno-
lence
Fi b ro mya l gia syndrome is a disease
with a higher female prevalence, caus-
ing poor sleep in 60-90% of subjects
(1, 3-6). In our case series of 30 conse-
cutive FMS patients symptoms such as
nocturnal awakening, poor sleep quali -
ty, fatigue, morning headache and wak-
ing up unrefreshed were very common
and did not significantly differ in the
two FMS groups in relation to daytime
sleepiness. However, no dramatic alte-
rations in PSG were seen, a fact which
does not support the severity of these
symptoms. Although Moldofsky et al.
(7) showed that slow wave sleep depri-
vation can exacerbate pain and asthenia
during the daytime, this can hardly ex-
plain hypersomnolence. The amount of
both stage 2 and REM phases was not
d i ffe rent betweent patients with and
without daytime hy p e rs o m n o l e n c e,
thus excluding REM deprivation as a
possible cause of excessive anxiety or
p s y ch o l ogical disord e rs wh i ch could
lead to an overestimation of symptoms. 
The number of arousals was ab o u t
twice as high in HS patients, but not
greater than 10 episodes/hour, a figure
which is rarely associated with hyper-
somnolence and far lower than that
reported in other diseases causing poor
s l e ep quality and hy p e rs o m n o l e n c e
(i.e. obstructive sleep apnea syndrome
[OSAS]). The analysis of arousals was
performed according to ASDA criteria
(16), which include both EEG arousals
and movement arousals lasting more
than 3 seconds. The alpha-delta intru-
sion, reported in a previous study as a
p o s s i ble factor disrupting sleep (10),
occurred sporadically in our patients;
Table I. Clinical data of the patients admitted to this study in accordance to hypersomnolence.
Hypersomnolence
Yes No p
N° of patients 16 14 ns
Epworth Sleepiness Scale score 15 ± 4 4 ± 2 0.001
N° of tender points 15 ± 2 12 ± 1 0.01
Pain (VAS) 72 ± 15 52 ± 13 0.05
Chronically poor sleep (%) 90 82 ns
Wake-up unrefreshed (%) 85 78 ns
Nocturnal awakening (%) 100 85 ns
Habitual snorers (%) 60 46 ns
Headache (%) 85 70 ns
Irritable bowel syndrome (%) 54 45 ns
Anxiety (VAS) 64 ± 11.2 54 ± 9.8 ns
Depression (VAS) 75 ± 15 63 ± 12.4 ns
Fatigue (VAS) 80 ± 12 62 ± 10 0.05
Table II. Pulmonary function data in 30 patients affected by fibromyalgia syndrome (FMS)
according to presence or absence of hypersomnolence.
Hypersomnolence
Yes No P
N° of patients 16 14
Forced Vital Capacity (FVC) (L) 3.0 ± 0.8 3.2 ± 0.7 ns
Forced Expiratory Volume in 1 sec (FEV1) (L) 2.4 ± 0.7 2.5 ± 0.8 ns
Residual Volume (RV) L) 1.6 ± 0.8 1.7 ± 0.6 ns
Total Lung Capacity (TLC) (L) 4.6 ± 1.2 4.7 ± 1.0 ns
Diffusing capacity of lung (TLco) (mmol/min/kPa) 5.3 ± 1 6.4 ± 1 0.01 
Diffusing capacity of alveolar membrane (Dm)
(mmol/min/kPa) 9.3 ± 0.8 11.4 ± 0.7 0.001
Volume of blood in alveolar capillaries (Vc) (L) 0.51 ± 0.05 0.53 ± 0.07 ns
Arterial blood O2 partial pressure (PaO2) (kPa) 11.8 ± 0.6 12.5 ± 0.5 0.01
Arterial blood CO2 partial pressure (PaCO2) (kPa) 4.6 ± 0.3 5.2 ± 0.4 0.01
Haemoglobin (Hb) (g/dl) 13.5 ± 1.0 13.6 ± 0.9 ns
Table III. Polysomnographic data in 30 fibromyalgia syndrome (FS) according to hyper-
somnolence.
Hypersomnolence
Yes No P
No. of patients 16 14
Sleep time (min.) 291 ± 46 334 ± 45 0.05
Stage 1 (% sleep time) 20 ± 5 22 ± 7 ns
Stage 2 (% sleep time) 36 ± 10 33 ± 8 ns
Stage 3 (% sleep time) 5 ± 2 12 ± 3 0.001
Stage 4 (% sleep time) 1 ± 0.5 4 ± 1 0.001
Rapid Eye Movement (% sleep time) 17 ± 9 18 ± 8 ns
Sleep efficiency (%) 79 ± 10 89 ± 6 0.01
Oxygen saturation (SaO2%) average during sleep 94.4 ± 1.9 95 ± 2 ns
SaO2% nadir during sleep 84.4 ± 4 86 ± 3 ns
Desaturation Event Frequency (events /hr) 11 ± 6 6 ± 5 0.05
Respiratory Disturbance Index (events/hr) 5 ± 3 7 ± 4 ns
Periodic Breathing (% sleep time) 18 ± 7 11 ± 7 0.05
Arousal index (N°/hr) 10 ± 3 6 ± 2 0.01
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therefore, a significant role in the path-
ogenesis of hy p e rsomnolence cannot
be alleged on the basis of our data. The
presence of another sleep-related respi-
ratory disorder, namely OSAS, was not
detected in our population of non-
obese FMS pat i e n t s , although more
than half were snorers - a result in ac-
cordance with Molony et al. (12). Also
the possibility of an upper airway resis-
tance syndrome seems to be excluded
by a number of arousals lower than 10
per hour.
It is thus possible that the usual criteria
applied to other patients (i.e. OSAS)
cannot be used in FMS patients. The
high female prevalence could play a
role as well, since females tend to over-
report symptoms of sleep disturbance
(18).
Periodic breathing and diffusion
abnormalities
The occurrence of PB for a mean 18%
of sleep time in FMS+HS pat i e n t s
could play an important role in the
‘poor sleep ’ complaints of these pa-
tients. In a previous paper we reported
this respiratory pattern during sleep in
FMS patients (6). It is well known that
periodic breathing may be linked to an
unstable functioning of the body’s ven-
tilation control system, elicited by the
transition from wakefulness to sleep,
which can occur even in normal sub-
jects for a limited amount of time.
When sleep becomes more consolidat-
ed PB usually disappears (19). Pain can
reduce sleep efficiency, causing more
f requent arousals and increasing the
chances for periodic bre athing to
appear. However, the occurrence of PB
in our patients (26 out of 30) was too
high to be explained only on this basis.
The absence of neurological diseases
or cardiac fa i l u re ex cluded the two
most common causes of PB. The fact
that TLco is reduced in FMS patients,
and even further reduced in those with
hy p e rs o m n o l e n c e, m ay throw some
light on the pathogenesis of PB. Again
we have not found previous reports of
this finding in FMS patients, probably
because this index was not routinely
m e a s u re d, since pulmonary function
and blood gases are usually normal, as
was the case in our patients. Wh e n
TLco is re d u c e d, a normal Pa O2 i s
maintained only by hy p e rve n t i l at i o n ,
which causes a PaCO2 decrease. 
We have no explanation for the lower
TLco in FMS pat i e n t s : p u l m o n a ry func-
tion tests were normal, Hb levels were
similar to normal subjects, all patients
were non-smokers, and when the mea-
s u rement was norm a l i zed by “ C O
back-tension” (COHb) the data did not
change. The overlap between relative
hypocapnia, hyperventilation and ven-
tilatory instability at sleep onset and
during the lighter stages of sleep (pos-
s i bly enhanced by pain-re l ated sleep
disruption) could perhaps explain the
o c c u rrence of periodic bre athing in FMS
subjects. The similarities with high alti-
tude periodic breathing - short apneas/
hy p o p n e a s , ‘poor sleep ’ c o m p l a i n t s ,
increased percentage of phase 1 sleep
(19) - further support the hypothesis of
a hypoxic-hypocapnic mechanism.
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